Navigation Links
Pharmalink Enters Manufacturing Agreement for Nefecon(R)
Date:10/31/2012

STOCKHOLM, October 31, 2012 /PRNewswire/ --

Pharmalink AB, a Swedish specialty pharma company, today announces it has entered into a contract with Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry for the manufacturing of Nefecon®, Pharmalink's lead product. Nefecon is being developed as the first on-label medication specifically aimed at addressing the underlying pathology of progressive IgA nephropathy, the most common form of primary glomerulonephritis and a leading cause of end-stage renal disease.

The agreement covers the manufacturing of Nefecon and is an important step in progressing the product towards the market. No commercial terms were disclosed.

Johan Häggblad, Managing Director of Pharmalink, said: "Despite the increasing recognition of IgA nephropathy as a significant cause of morbidity and mortality, no specific medications have been developed and introduced to the market. In that context, our development programme for Nefecon is seen as one of the most significant in IgA nephropathy clinical research. We have already shown positive results in an open-labelled Phase II trial evaluating Nefecon's safety and efficacy and, with Patheon, we will be working with one of the pharmaceutical industry's best-respected manufacturers as Nefecon advances towards pivotal trials."

Nefecon is an enteric formulation of a locally-acting and potent corticosteroid which down regulates the IgA nephropathy disease process in the kidney through suppression of the gastrointestinal immune system, thus exploiting the pivotal role the gastrointestinal tract plays in the overall immune response. The target group for Nefecon is the approximately 40% patients with the more aggressive form of the disease and who are at risk of developing end-stage renal disease. The ultimate aim is to provide an alternative to dialysis and transplantation. Pharmalink has received orphan drug designation by the US Food and Drug Administration (FDA) for Nefecon.

Nefeconwas invented at Uppsala University (Sweden) and was acquired by Pharmalink in 2004. Nefecon® is delivered using the proprietary TARGIT® drug delivery technology which enables the localized delivery of drugs to the lower small intestine or colonic regions of the gastrointestinal tract. Pharmalink has an exclusive licence to Targit® technology for the development of Nefecon® from Archimedes Pharma.

About Pharmalink

Pharmalink is a Swedish specialty pharma company developing high-value products for niche indications. Pharmalink draws on its extensive experience of pharmaceutical development and marketing and the excellence of medical science in Sweden to identify and progress products that address significant unmet medical needs. With a successful history in pharmaceutical sales and marketing, and highly experienced, dynamic management team, Pharmalink is currently focused on the development of valuable, de-risked projects using a repurposing and reformulation strategy. It has two late-stage clinical phase products under development, Nefecon® and Busulipo™, having successfully divested its Xepol® product in 2010. Pharmalink is actively seeking opportunities to acquire or in-licence product opportunities in niche and hospital care indications. Visit http://www.pharmalink.se for further information.

About Patheon

Patheon Inc. (TSX: PTI) is a leading global provider of contract development and manufacturing services to the global pharmaceutical industry. The company provides the highest quality products and services to approximately 300 of the world's leading pharmaceutical and biotechnology companies. Patheon's services range from preclinical development through commercial manufacturing of a full array of solid and sterile dosage forms.

The company's comprehensive range of fully integrated Pharmaceutical Development Services includes pre-formulation, formulation, analytical development, clinical manufacturing, scale-up and commercialization. The company's integrated development and manufacturing network of nine manufacturing facilities and nine development centers across North America and Europe, enables customer products to be launched with confidence anywhere in the world. For more information please visit http://www.patheon.com.

For further information, please contact:

Pharmalink AB:
Johan Häggblad, Managing Director, +46(0)70-668-0644
johan.haggblad@pharmalink.se
http://www.pharmalink.se

Citigate Dewe Rogerson:
Chris Gardner/Nina Enegren, +44(0)207-638-9571


'/>"/>
SOURCE Pharmalink
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmalink Consulting Appoints Chief Operating Officer for the Americas
2. Pharmalink AB Strengthens Senior Management Team
3. Lung Cancer Alliance Congratulates 75 Medical Centers For Moving Swiftly And Responsibly On Lung Cancer Screening
4. Stiefel, a GSK company, enters agreement with Welichem Biotech, Inc. to acquire a novel topical agent for psoriasis and atopic dermatitis
5. CyberKnife System and the da Vinci Surgical System in Concord Medical Centers Achieve Over RMB 10 Million in Medical Revenue Since Opening in February
6. 3 Pediatric Centers that Offer SynCardia Total Artificial Heart Named in Top 10 for "Best Childrens Hospitals"
7. Abaxis Enters Into Definitive Agreement To Deliver 300 Piccolo Xpress Instruments For A Four-Year Drug Clinical Trial
8. The Galien Foundation Announces Roster of Luminary Presenters for Third Galien Forum; Program Highlights Include CEO Panel, Panel on Alzheimers Disease Innovation, Nobel Laureate Elie Wiesel
9. ApolloMed ACO Selected To Participate In A Transformative New Initiative Sponsored by the Centers for Medicare and Medicaid Services
10. Spine Pain Management Opens Two Additional Affiliate Diagnostic Centers in Florida
11. Caspase Inhibitor Enters Clinical Trial In Islet Transplantation As Treatment For Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... bioLytical Laboratories, ein Weltführer bei schnellen Tests für ... Apothekenbundes von Kenia eingeführt. Continue Reading ... ... Test! (PRNewsFoto/bioLytical Laboratories) ... http://photos.prnewswire.com/prnh/20161201/444905 ) bioLytical wurde durch die ...
(Date:12/2/2016)... , December 2, 2016 Orthopedic Implants ... Support) is Expected to Gain a Significant Market Share Owing ... Ailments  ... According to a new ... Medical Implants Sterile Packaging: Clamshell Product Type Segment Projected to ...
(Date:12/2/2016)... December 2, 2016 On Thursday, the ... in red, while the Dow Jones Industrial Average managed to ... of US markets, which prompted Stock-callers this morning to look ... (NASDAQ: NUVA ), Smith & Nephew PLC (NYSE: ... NXTM ), and Cesca Therapeutics Inc. (NASDAQ: KOOL ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... ‘Tis the season for giving! Today, 20 creative ... National Family Partnership and the Drug Enforcement Administration as part of the National Red ... 10 winning schools who decorated their campuses with this year’s Red Ribbon Week theme: ...
(Date:11/30/2016)... , ... November 30, 2016 , ... ... they now offer a comprehensive in-house dental plan for all patients. Understanding that ... a plan that gives patients a number of perks, including discounts on many ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... Deloitte Wisconsin 75, an annual ranking and recognition of the largest closely held ... list, having ranked from 2008-2016. In addition, Standard Process was awarded the Talent ...
(Date:11/30/2016)... ... November 30, 2016 , ... Center For ... announced the opening of a new residential mental health treatment program in Chino ... issues such as severe anxiety, depression, bi-polar disorder, and other related issues. , ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... and stylish design wanted by today’s consumers at an affordable price, is now ... says the new watch is “a game changer” when it comes to the ...
Breaking Medicine News(10 mins):